The effects of naloxone on human breast cancer progression: In vitro and in vivo studies on MDA.MB231 cells

Sabrina Bimonte, Antonio Barbieri, Marco Cascella, Domenica Rea, Giuseppe Palma, Vitale Del Vecchio, Cira Antonietta Forte, Francesco Del Prato, Claudio Arra, Arturo Cuomo

Research output: Contribution to journalArticle

Abstract

Background: Naloxone is viewed as a specific competitive opioid antagonist acting at the level of opioid receptors (µ, δ, and κ) with blended agonist-adversary or agonist action. The role of naloxone in tumor cell growth has been poorly studied in human cancer cell lines. Materials and methods: In the present study, we report findings from in vitro and in vivo experiments performed to evaluate the effects of naloxone on human breast cancer cell growth and progression. In vitro assays were conducted on estrogen receptor-negative human breast carcinoma cells, MDA.MB231, treated with naloxone at different concentrations (10-100 µM). In vivo experiments were performed on a mouse model of human triple-negative breast cancer generated by using MDA.MB231 injected subcutaneously in mice. Naloxone was daily intraperitoneally injected in mice at 0.357 mg/kg for 2 weeks and at 0.714 mg/kg for the next 2 weeks. Microvessels formation was detected by fluorescein isothiocyanate-dextran (100 µL) injected into the tail vein of mice and confirmed by immunohistochemistry with CD31 on mice tumor sections. Results: In vitro tests showed that the cell proliferation of MDA.MB231 was inhibited by naloxone in a dose-dependent manner, whereas the cell death was increased. In vivo studies demonstrated that tumors of mice treated with naloxone were significantly smaller than those observed in the control groups, as long as naloxone was administered. Finally, naloxone was not able to impair the microvessel formation in tumors of treated mice. Conclusion: Our data showed, for the first time, that naloxone reduced breast cancer progression without affecting angiogenesis.

Original languageEnglish
Pages (from-to)185-191
Number of pages7
JournalOncoTargets and Therapy
Volume11
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Naloxone
Breast Neoplasms
Neoplasms
Microvessels
In Vitro Techniques
Triple Negative Breast Neoplasms
Narcotic Antagonists
Opioid Receptors
Growth
Estrogen Receptors
Tail
Veins
Cell Death
Immunohistochemistry
Cell Proliferation
Cell Line
Control Groups

Keywords

  • Angiogenesis
  • Breast cancer
  • Microvessel formation
  • Naloxone
  • Proliferation

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

The effects of naloxone on human breast cancer progression : In vitro and in vivo studies on MDA.MB231 cells. / Bimonte, Sabrina; Barbieri, Antonio; Cascella, Marco; Rea, Domenica; Palma, Giuseppe; Del Vecchio, Vitale; Forte, Cira Antonietta; Del Prato, Francesco; Arra, Claudio; Cuomo, Arturo.

In: OncoTargets and Therapy, Vol. 11, 01.01.2018, p. 185-191.

Research output: Contribution to journalArticle

Bimonte, Sabrina ; Barbieri, Antonio ; Cascella, Marco ; Rea, Domenica ; Palma, Giuseppe ; Del Vecchio, Vitale ; Forte, Cira Antonietta ; Del Prato, Francesco ; Arra, Claudio ; Cuomo, Arturo. / The effects of naloxone on human breast cancer progression : In vitro and in vivo studies on MDA.MB231 cells. In: OncoTargets and Therapy. 2018 ; Vol. 11. pp. 185-191.
@article{151c72c1cd3f43a282c42a469b65457f,
title = "The effects of naloxone on human breast cancer progression: In vitro and in vivo studies on MDA.MB231 cells",
abstract = "Background: Naloxone is viewed as a specific competitive opioid antagonist acting at the level of opioid receptors (µ, δ, and κ) with blended agonist-adversary or agonist action. The role of naloxone in tumor cell growth has been poorly studied in human cancer cell lines. Materials and methods: In the present study, we report findings from in vitro and in vivo experiments performed to evaluate the effects of naloxone on human breast cancer cell growth and progression. In vitro assays were conducted on estrogen receptor-negative human breast carcinoma cells, MDA.MB231, treated with naloxone at different concentrations (10-100 µM). In vivo experiments were performed on a mouse model of human triple-negative breast cancer generated by using MDA.MB231 injected subcutaneously in mice. Naloxone was daily intraperitoneally injected in mice at 0.357 mg/kg for 2 weeks and at 0.714 mg/kg for the next 2 weeks. Microvessels formation was detected by fluorescein isothiocyanate-dextran (100 µL) injected into the tail vein of mice and confirmed by immunohistochemistry with CD31 on mice tumor sections. Results: In vitro tests showed that the cell proliferation of MDA.MB231 was inhibited by naloxone in a dose-dependent manner, whereas the cell death was increased. In vivo studies demonstrated that tumors of mice treated with naloxone were significantly smaller than those observed in the control groups, as long as naloxone was administered. Finally, naloxone was not able to impair the microvessel formation in tumors of treated mice. Conclusion: Our data showed, for the first time, that naloxone reduced breast cancer progression without affecting angiogenesis.",
keywords = "Angiogenesis, Breast cancer, Microvessel formation, Naloxone, Proliferation",
author = "Sabrina Bimonte and Antonio Barbieri and Marco Cascella and Domenica Rea and Giuseppe Palma and {Del Vecchio}, Vitale and Forte, {Cira Antonietta} and {Del Prato}, Francesco and Claudio Arra and Arturo Cuomo",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/OTT.S145780",
language = "English",
volume = "11",
pages = "185--191",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The effects of naloxone on human breast cancer progression

T2 - In vitro and in vivo studies on MDA.MB231 cells

AU - Bimonte, Sabrina

AU - Barbieri, Antonio

AU - Cascella, Marco

AU - Rea, Domenica

AU - Palma, Giuseppe

AU - Del Vecchio, Vitale

AU - Forte, Cira Antonietta

AU - Del Prato, Francesco

AU - Arra, Claudio

AU - Cuomo, Arturo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Naloxone is viewed as a specific competitive opioid antagonist acting at the level of opioid receptors (µ, δ, and κ) with blended agonist-adversary or agonist action. The role of naloxone in tumor cell growth has been poorly studied in human cancer cell lines. Materials and methods: In the present study, we report findings from in vitro and in vivo experiments performed to evaluate the effects of naloxone on human breast cancer cell growth and progression. In vitro assays were conducted on estrogen receptor-negative human breast carcinoma cells, MDA.MB231, treated with naloxone at different concentrations (10-100 µM). In vivo experiments were performed on a mouse model of human triple-negative breast cancer generated by using MDA.MB231 injected subcutaneously in mice. Naloxone was daily intraperitoneally injected in mice at 0.357 mg/kg for 2 weeks and at 0.714 mg/kg for the next 2 weeks. Microvessels formation was detected by fluorescein isothiocyanate-dextran (100 µL) injected into the tail vein of mice and confirmed by immunohistochemistry with CD31 on mice tumor sections. Results: In vitro tests showed that the cell proliferation of MDA.MB231 was inhibited by naloxone in a dose-dependent manner, whereas the cell death was increased. In vivo studies demonstrated that tumors of mice treated with naloxone were significantly smaller than those observed in the control groups, as long as naloxone was administered. Finally, naloxone was not able to impair the microvessel formation in tumors of treated mice. Conclusion: Our data showed, for the first time, that naloxone reduced breast cancer progression without affecting angiogenesis.

AB - Background: Naloxone is viewed as a specific competitive opioid antagonist acting at the level of opioid receptors (µ, δ, and κ) with blended agonist-adversary or agonist action. The role of naloxone in tumor cell growth has been poorly studied in human cancer cell lines. Materials and methods: In the present study, we report findings from in vitro and in vivo experiments performed to evaluate the effects of naloxone on human breast cancer cell growth and progression. In vitro assays were conducted on estrogen receptor-negative human breast carcinoma cells, MDA.MB231, treated with naloxone at different concentrations (10-100 µM). In vivo experiments were performed on a mouse model of human triple-negative breast cancer generated by using MDA.MB231 injected subcutaneously in mice. Naloxone was daily intraperitoneally injected in mice at 0.357 mg/kg for 2 weeks and at 0.714 mg/kg for the next 2 weeks. Microvessels formation was detected by fluorescein isothiocyanate-dextran (100 µL) injected into the tail vein of mice and confirmed by immunohistochemistry with CD31 on mice tumor sections. Results: In vitro tests showed that the cell proliferation of MDA.MB231 was inhibited by naloxone in a dose-dependent manner, whereas the cell death was increased. In vivo studies demonstrated that tumors of mice treated with naloxone were significantly smaller than those observed in the control groups, as long as naloxone was administered. Finally, naloxone was not able to impair the microvessel formation in tumors of treated mice. Conclusion: Our data showed, for the first time, that naloxone reduced breast cancer progression without affecting angiogenesis.

KW - Angiogenesis

KW - Breast cancer

KW - Microvessel formation

KW - Naloxone

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=85040945028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040945028&partnerID=8YFLogxK

U2 - 10.2147/OTT.S145780

DO - 10.2147/OTT.S145780

M3 - Article

AN - SCOPUS:85040945028

VL - 11

SP - 185

EP - 191

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -